Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veterinary Parasitic Vaccine Development

Inquiry Now

Parasites show a significant impact on the health of both companion animals and livestock worldwide, reducing livestock productivity. Vaccination is considered one of the options for parasite control. In the face of veterinary parasitic diseases, BioVenic promotes animal health and specializes in designing comprehensive solutions to the challenges of animal parasites. With a keen sense of science, advanced technology and a dedication to animal welfare, BioVenic strives to help researchers develop highly effective parasite vaccines that not only protect the health of animals but also contribute to the overall welfare of animals.

Our Services

Challenges in the development of veterinary parasite vaccines arise from the intricate life cycle of the parasite, antigenic differences across hosts and regions, immune evasion strategies employed by the parasite, and the complexity of generating an effective immune response. BioVenic offers the following veterinary vaccine development services to better protect animals against the threat of parasites.

Design of veterinary parasitic vaccines. (BioVenic Original) Fig.1 Design of veterinary parasitic vaccines. (BioVenic Original)

Parasitic Antigen Discovery

Screening for effective candidate vaccine antigens must utilize effective screening tools and methods in conjunction with the characteristics of the pathogens themselves. Whether it is traditional parasite antigen screening based on antigen-antibody specific binding, newer methods such as screening based on animal parasite cDNA libraries, or the application of genomics and proteomics, BioVenic offers these services to identify key antigens specific to parasitic pathogens. This service lays the groundwork for the development of targeted animal parasite vaccines and improves the ability of vaccines to trigger potent immune responses against these parasites.

Formulation Solutions

Typically, vaccines consist of antigens, adjuvants and additives as supporting components to maintain high antigenic activity and ensure that the vaccine can produce the appropriate level and type of immune response in the host after vaccination, while the addition of the supporting components ensures the stability of the vaccine for transportation and shelf life. In addition to antigen discovery, BioVenic also provides veterinary parasitic vaccine formulation solutions to solve your troubles in vaccine adjuvants and delivery systems, help you develop veterinary parasitic vaccines on new technology platforms.

Safety and Efficacy Assessment

One of the main reasons for the slow progress in veterinary parasitic vaccine development is the lack of understanding of the complexity of protective immunity and the role of adjuvants in the balance between enhancing the immune response and generating side effects. BioVenic specializes in providing comprehensive in vitro and in vivo evaluation services for veterinary parasitic vaccines.

Veterinary Parasitic Vaccine Development Platforms

Due to the complexity of veterinary parasitic infections, vaccine development is often hampered by production constraints and inadequate immune responses. BioVenic offers not only traditional vaccine technology platforms, but also new vaccine technology platforms to maximize your choice. The table below lists advantages and limitations of each vaccine technology platform.

Platforms Advantages Limitations
Live Attenuated Parasitic Vaccine
  • Long-lasting immunity.
  • No adjuvants required.
  • High requirements for storage and transportation.
  • Manufacturing challenge.
  • Risk for infection.
Recombinant Parasitic Vaccine
  • Safe.
  • Strong humoral response.
  • Difficult for multivalent formulations.
  • Adjuvants required.
DNA Parasitic Vaccine
  • Safe.
  • Stable at room temperature.
  • Low costs.
  • Options for multivalency
  • Potential risk at genetic integration.
  • Adjuvants required.
mRNA Parasitic Vaccine
  • Safe.
  • No genetic integration risks.
  • Easy to manufacture.
  • Options for multivalency.
  • Not stable.
  • High production costs.

Applications of Veterinary Parasitic Vaccines

The development of veterinary parasitic vaccines plays an important role in animal health protection. Vaccines can prevent diseases caused by parasite-infected animals, improve the efficiency of animal husbandry, reduce the use of drugs, protect the environment and the ecological balance. At the same time, vaccines reduce the incidence of zoonotic diseases and improve the quality of life of livestock, poultry, companion animals, aquaculture species and more.

Our Advantages

Elaborate Vaccine Formulation Design

BioVenic provides vaccine formulation development services to assist you in improving the immunogenicity of veterinary parasitic vaccine antigens and increasing the success rate of immunization.

Powerful Antigen Discovery

Relying on our knowledge of animal parasites and multiple animal species, BioVenic has the ability to screen and characterize highly immunogenic antigens to support animal infectious disease preventive vaccine development.

Diversified Technology Platform Offering

BioVenic provides you with different kinds of vaccine technology development platforms, choose your most preferred one to improve the success rate of veterinary parasitic vaccine development.

If you're seeking solutions to combat veterinary parasitic diseases and safeguard animal health, including livestock, poultry, companion animals, aquaculture species and more, our doors are open for inquiries. BioVenic is ready to collaborate with you and provide tailored solutions. Please contact us for further consulting for your vaccine development project.

Reference

  1. Versteeg, Leroy, et al. "Enlisting the mRNA vaccine platform to combat parasitic infections." Vaccines 7.4 (2019): 122.
Inquiry Basket